Moderna Shares Fall More Than 25% on Apparent Early Release of Intismeran Data

Moderna shares fell more than 25% and Merck shares fell more than 3% on October 22, 2026, after apparent early release of data on intismeran autogene, a personalized mRNA cancer vaccine the companies co-develop, Investing.com reported. The release was unscheduled. Moderna's August Phase 3 melanoma result rested on an interim analysis, an early look at incomplete trial data.